{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:09:37Z","timestamp":1792796977400,"version":"4.5.0"},"reference-count":119,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder featured by increased platelet destruction and deficient megakaryocyte maturation. First-line treatments include corticosteroids, intravenous immunoglobulin and intravenous anti-D immunoglobulin. Second-line treatments consist of rituximab, thrombopoietin receptor agonists and splenectomy. Although most patients benefit from these treatments, an individualized treatment approach is warranted due to the large heterogeneity among ITP patients. In addition, ITP patients may relapse and there remains a subset of patients who become refractory to treatments. The management of these refractory patients is still a challenge. This review aims to summarize emerging therapeutic approaches for refractory ITP in several categories according to their different targets, including macrophages, platelets\/megakaryocytes, T cells, B cells, and endothelial cells. Moreover, current management strategies and combination regimens of refractory ITP are also discussed.<\/jats:p>","DOI":"10.3389\/fimmu.2022.953716","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T03:02:02Z","timestamp":1659927722000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["Current therapeutic strategies and perspectives in refractory ITP: What have we learned recently?"],"prefix":"10.3389","volume":"13","author":[{"given":"Yue","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: Report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2016.12.016","article-title":"[Epidemiology and pharmacoepidemiology of immune thrombocytopenia]","volume":"38","author":"Moulis","year":"2017","journal-title":"Rev Med Interne"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-603365","article-title":"How I treat refractory immune thrombocytopenia","volume":"128","author":"Cuker","year":"2016","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-704734","article-title":"Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia","volume":"128","author":"Mah\u00e9vas","year":"2016","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003599","article-title":"Identifying and treating refractory itp: Difficulty in diagnosis and role of combination treatment","volume":"135","author":"Miltiadous","year":"2020","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1365-2141.2008.07275.x","article-title":"Refractory immune thrombocytopenic purpura: Current strategies for investigation and management","volume":"143","author":"Psaila","year":"2008","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2003-11-3908","article-title":"Long-term outcomes in adults with chronic itp after splenectomy failure","volume":"104","author":"McMillan","year":"2004","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V97.9.2549","article-title":"Morbidity and mortality in adults with idiopathic thrombocytopenic purpura","volume":"97","author":"Portielje","year":"2001","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04786-y","article-title":"Refractory primary immune thrombocytopenia (Itp): Current clinical challenges and therapeutic perspectives","volume":"101","author":"Vianelli","year":"2022","journal-title":"Ann Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.116","article-title":"Prtx-100 and methotrexate in patients with active rheumatoid arthritis: A phase ib randomized, double-blind, placebo-controlled, dose-escalation study","volume":"3","author":"Bernton","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00496","article-title":"Engineering of fc multimers as a protein therapy for autoimmune disease","volume":"11","author":"Fitzpatrick","year":"2020","journal-title":"Front In Immunol"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1517\/14712598.2013.800856","article-title":"Rozrolimupab, a first-in-Class recombinant monoclonal antibody product for primary immune thrombocytopaenia","volume":"13","author":"Easdale","year":"2013","journal-title":"Expert Opin Biol Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.1038\/ncomms8737","article-title":"Desialylation is a mechanism of fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia","volume":"6","author":"Li","year":"2015","journal-title":"Nat Commun"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2015.01.001","article-title":"Loss of autophagy leads to failure in megakaryopoiesis, megakaryocyte differentiation, and thrombopoiesis in mice","volume":"43","author":"Cao","year":"2015","journal-title":"Exp Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.21037\/atm.2019.03.04","article-title":"Enhancing autophagy protects platelets in immune thrombocytopenia patients","volume":"7","author":"Wang","year":"2019","journal-title":"Ann Transl Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1160\/th14-04-0342","article-title":"Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia","volume":"113","author":"Ni","year":"2017","journal-title":"Thromb Haemostasis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1342913","article-title":"Percentages of pd-1cd4t cells and pd-L1dcs are increased and spd-1 level is elevated in patients with immune thrombocytopenia","volume":"14","author":"Wang","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-847624","article-title":"Low-dose chidamide restores immune tolerance in itp in mice and humans","volume":"133","author":"Zhao","year":"2019","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008477","article-title":"Low-dose decitabine modulates T cell homeostasisand restores immune tolerance in immune thrombocytopenia","volume":"138","author":"Han","year":"2021","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.630693","article-title":"Low-dose decitabine inhibits cytotoxic T lymphocytes-mediated platelet destruction via modulating pd-1 methylation in immune thrombocytopenia","volume":"12","author":"Han","year":"2021","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":":9\u201317","DOI":"10.1159\/000517989","article-title":"The mechanistic effects and clinical applications of various derived mesenchymal stem cells in immune thrombocytopenia","volume":"145","author":"He","year":"2022","journal-title":"Acta Haematologica"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2003-08-2672","article-title":"Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic itp","volume":"103","author":"McMillan","year":"2004","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1669921","article-title":"Proteasome inhibition with bortezomib induces apoptosis of long-lived plasma cells in steroid-resistant or relapsed immune thrombocytopaenia","volume":"118","author":"Li","year":"2018","journal-title":"Thromb haemostasis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04571.x","article-title":"Megakaryocytes, malignancy and bone marrow vascular niches","volume":"10","author":"Psaila","year":"2012","journal-title":"J Thromb Haemost"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.689663","article-title":"Predictive value of high icam-1 level for poor treatment response to low-dose decitabine in adult corticosteroid resistant itp patients","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13580","article-title":"Ivig increases interleukin-11 levels, which in turn contribute to increased platelets, vwf and fviii in mice and humans","volume":"204","author":"Nguyen","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000612","article-title":"An update on the pathophysiology of immune thrombocytopenia","volume":"27","author":"Semple","year":"2020","journal-title":"Curr Opin In Hematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":":16","DOI":"10.3390\/jcm6020016","article-title":"Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (Itp)","volume":"6","author":"Zufferey","year":"2017","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-166439","article-title":"Of mice and men: An open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of syk","volume":"113","author":"Podolanczuk","year":"2009","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110297","article-title":"Rilzabrutinib, an oral btk inhibitor, in immune thrombocytopenia","volume":"386","author":"Kuter","year":"2022","journal-title":"New Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25646","article-title":"A prospective, multicenter study of low dose decitabine in adult patients with refractory immune thrombocytopenia","volume":"94","author":"Zhou","year":"2019","journal-title":"Am J Hematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00030-2","article-title":"Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: A multicentre, randomised, open-label, phase 2 trial","volume":"8","author":"Sun","year":"2021","journal-title":"Lancet Haematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002003","article-title":"Phase 2 multiple-dose study of an fcrn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia","volume":"4","author":"Robak","year":"2020","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25680","article-title":"Phase 2 study of efgartigimod, a novel fcrn antagonist, in adult patients with primary immune thrombocytopenia","volume":"95","author":"Newland","year":"2019","journal-title":"Am J Hematol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2015-07-657981","article-title":"Sirolimus is effective in Relapsed\/Refractory autoimmune cytopenias: Results of a prospective multi-institutional trial","volume":"127","author":"Bride","year":"2016","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.4929.4929","article-title":"Safety and efficacy of prtx-100, a highly purified form of staphylococcal protein a, in patients with immune thrombocytopenia (Itp)","volume":"128","author":"Bussel","year":"2016","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438804","article-title":"Rozrolimupab, a mixture of 25 recombinant human monoclonal rhd antibodies, in the treatment of primary immune thrombocytopenia","volume":"120","author":"Robak","year":"2012","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0927-1","article-title":"Fostamatinib: First global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16959","article-title":"Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia","volume":"190","author":"Boccia","year":"2020","journal-title":"Br J Haematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12777","article-title":"Thromboembolism in adults with primary immune thrombocytopenia: A systematic literature review and meta-analysis","volume":"97","author":"Doobaree","year":"2016","journal-title":"Eur J Haematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/20406207211010875","article-title":"Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib","volume":"12","author":"Cooper","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-852491","article-title":"Fostamatinib for the treatment of chronic immune thrombocytopenia","volume":"133","author":"Connell","year":"2019","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.662223","article-title":"Bruton's tyrosine kinase (Btk) inhibitors and autoimmune diseases: Making sense of btk inhibitor specificity profiles and recent clinical trial successes and failures","volume":"12","author":"Ringheim","year":"2021","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","article-title":"Bruton tyrosine kinase inhibitor ibrutinib (Pci-32765) has significant activity in patients with Relapsed\/Refractory b-cell malignancies","volume":"31","author":"Advani","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.85","article-title":"Targeting bruton's tyrosine kinase with ibrutinib in b-cell malignancies","volume":"97","author":"Wang","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13351","article-title":"A phase I trial of Prn1008, a novel reversible covalent inhibitor of bruton's tyrosine kinase, in healthy volunteers","volume":"83","author":"Smith","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01482-5","article-title":"Orelabrutinib: First approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1289","article-title":"Immune evasion by staphylococci","volume":"3","author":"Foster","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1317181111","article-title":"Release of protein a from the cell wall of staphylococcus aureus","volume":"111","author":"Becker","year":"2014","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B52","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.147.6.1877","article-title":"Human iga and igg F(Ab')2 that bind to staphylococcal protein a belong to the vhiii subgroup","volume":"147","author":"Sasso","year":"1991","journal-title":"J Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14985","article-title":"A highly purified form of staphylococcal protein a alleviates murine immune thrombocytopenia (Itp)","volume":"183","author":"Kapur","year":"2018","journal-title":"Br J Haematol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20297","article-title":"Pharmacokinetic effects of 4c9, an anti-fcrn antibody, in rats: Implications for the use of fcrn inhibitors for the treatment of humoral autoimmune and alloimmune conditions","volume":"94","author":"Getman","year":"2005","journal-title":"J Pharm Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.11.040","article-title":"Generation of two high affinity anti-mouse fcrn antibodies: Inhibition of igg recycling in wild type mice and effect in a mouse model of immune thrombocytopenia","volume":"66","author":"Smith","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":":eaan1208","DOI":"10.1126\/scitranslmed.aan1208","article-title":"The fcrn inhibitor rozanolixizumab reduces human serum igg concentration: A randomized phase 1 study","volume":"9","author":"Kiessling","year":"2017","journal-title":"Sci Trans Med"},{"key":"B57","doi-asserted-by":"crossref","DOI":"10.1038\/nbt1143","article-title":"Engineering the fc region of immunoglobulin G to modulate in vivo antibody levels","volume":"23","author":"Vaccaro","year":"2005","journal-title":"Nat Biotechnol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal fc receptor antagonist efgartigimod safely and sustainably reduces iggs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"key":"B60","doi-asserted-by":"publisher","first-page":"R192","DOI":"10.1186\/ar4024","article-title":"Fully recombinant Igg2a fc multimers (Stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in mice","volume":"14","author":"Jain","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":":e121905","DOI":"10.1172\/jci.insight.121905","article-title":"A recombinant human Igg1 fc multimer designed to mimic the active fraction of ivig in autoimmunity","volume":"4","author":"Zhang","year":"2019","journal-title":"JCI Insight"},{"key":"B62","doi-asserted-by":"crossref","first-page":"365ra158","DOI":"10.1126\/scitranslmed.aaf9418","article-title":"Elucidating the interplay between igg-fc valency and fc\u03b3r activation for the design of immune complex inhibitors","volume":"8","author":"Ortiz","year":"2016","journal-title":"Sci Trans Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s42003-018-0149-9","article-title":"Engineered hexavalent fc proteins with enhanced fc-gamma receptor avidity provide insights into immune-complex interactions","volume":"1","author":"Rowley","year":"2018","journal-title":"Commun Biol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"17049","DOI":"10.1038\/s41598-017-17255-8","article-title":"Multivalent fc\u03b3-receptor engagement by a hexameric fc-fusion protein triggers fc\u03b3-receptor internalisation and modulation of fc\u03b3-receptor functions","volume":"7","author":"Qureshi","year":"2017","journal-title":"Sci Rep"},{"key":"B65","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.79.10.3275","article-title":"Human neutrophil fc gamma receptor distribution and structure","volume":"79","author":"Fleit","year":"1982","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B66","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM198605083141907","article-title":"Treatment of refractory immune thrombocytopenic purpura with an anti-fc gamma-receptor antibody","volume":"314","author":"Clarkson","year":"1986","journal-title":"New Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36451","article-title":"Fc receptors in immune thrombocytopenias: A target for immunomodulation","volume":"118","author":"Psaila","year":"2008","journal-title":"J Clin Invest"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-664656","article-title":"Monovalent fc receptor blockade by an anti-fc\u03b3 Receptor\/Albumin fusion protein ameliorates murine itp with abrogated toxicity","volume":"127","author":"Yu","year":"2016","journal-title":"Blood"},{"key":"B69","article-title":"Rozrolimupab, symphobodies against rhesus d, for the potential prevention of hemolytic disease of the newborn and the treatment of idiopathic thrombocytopenic purpura","volume":"12","author":"Stasi","year":"2010","journal-title":"Curr Opin Mol Ther"},{"key":"B70","article-title":"Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura","volume":"106","author":"Gaines","year":"2005","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3109\/09537100903144617","article-title":"Efficacy and safety of anti-d for treatment of adults with immune thrombocytopenia","volume":"20","author":"Naithani","year":"2009","journal-title":"Platelets"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12957","article-title":"Cd44 antibody-mediated amelioration of murine immune thrombocytopenia (Itp): Mouse background determines the effect of fc\u03b3riib genetic disruption","volume":"55","author":"Crow","year":"2015","journal-title":"Transfusion"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009497","article-title":"Anti-inflammatory activity of Cd44 antibodies in murine immune thrombocytopenia is mediated by fc\u03b3 receptor inhibition","volume":"137","author":"Norris","year":"2021","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2018.1513476","article-title":"Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content","volume":"30","author":"Revilla","year":"2019","journal-title":"Platelets"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.225987","article-title":"Slc35a1 deficiency causes thrombocytopenia due to impaired megakaryocytopoiesis and excessive platelet clearance in the liver","volume":"106","author":"Ma","year":"2021","journal-title":"Haematologica"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-598722","article-title":"Autophagy is induced upon platelet activation and is essential for hemostasis and thrombosis","volume":"126","author":"Ouseph","year":"2015","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.01.011","article-title":"Targeting autophagy as a potential therapeutic approach for immune thrombocytopenia therapy","volume":"100","author":"Shan","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12935-019-0779-0","article-title":"Megakaryocytic dysfunction in immune thrombocytopenia is linked to autophagy","volume":"19","author":"Sun","year":"2019","journal-title":"Cancer Cell Int"},{"key":"B79","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.exphem.2020.08.001","article-title":"Sirolimus is effective for primary Relapsed\/Refractory autoimmune cytopenia: A multicenter study","volume":"89","author":"Li","year":"2020","journal-title":"Exp Hematol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00110","article-title":"Sirolimus as rescue therapy for Refractory\/Relapsed immune thrombocytopenia: Results of a single-center, prospective, single-arm study","volume":"7","author":"Feng","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13029","article-title":"A multi-centre, single-arm, open-label study evaluating the safety and efficacy of fixed dose rituximab in patients with refractory, relapsed or chronic idiopathic thrombocytopenic purpura (R-Itp1000 study)","volume":"167","author":"Tran","year":"2014","journal-title":"Br J Haematol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-008-9223-2","article-title":"Decreased DNA methyltransferase 3a and 3b mrna expression in peripheral blood mononuclear cells and increased plasma sah concentration in adult patients with idiopathic thrombocytopenic purpura","volume":"28","author":"Tao","year":"2008","journal-title":"J Clin Immunol"},{"key":"B83","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1053\/j.seminhematol.2005.05.002","article-title":"Pharmacology of 5-Aza-2'-Deoxycytidine (Decitabine)","volume":"42","author":"Momparler","year":"2005","journal-title":"Semin Hematol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-267435","article-title":"Contributions of trail-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia","volume":"116","author":"Yang","year":"2010","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/950903","article-title":"Upregulated pd-1 expression is associated with the development of systemic lupus erythematosus, but not the pd-1.1 allele of the Pdcd1 gene","volume":"2014","author":"Jiao","year":"2014","journal-title":"Int J Genomics"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr529","article-title":"Stimulation of the pd-1\/Pdl-1 T-cell Co-inhibitory pathway is effective in treatment of experimental autoimmune glomerulonephritis","volume":"27","author":"Reynolds","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B87","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20022119","article-title":"Critical role of the programmed death-1 (Pd-1) pathway in regulation of experimental autoimmune encephalomyelitis","volume":"198","author":"Salama","year":"2003","journal-title":"J Exp Med"},{"key":"B88","doi-asserted-by":"crossref","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the pd-1 gene encoding an itim motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1177\/1076029614562952","article-title":"Soluble programmed death 1 (Pd-1) is decreased in patients with immune thrombocytopenia (Itp): Potential involvement of pd-1 pathway in itp immunopathogenesis","volume":"22","author":"Birtas Atesoglu","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000017608","article-title":"Pd-1\/Pd-L1 pathway activation restores the imbalance of Th1\/Th2 and Treg\/Th17 cells subtypes in immune thrombocytopenic purpura patients","volume":"98","author":"Wu","year":"2019","journal-title":"Med (Baltimore)"},{"key":"B91","doi-asserted-by":"crossref","DOI":"10.1016\/j.humimm.2014.09.018","article-title":"Foxp3 methylation status in children with primary immune thrombocytopenia - sciencedirect","volume":"75","author":"Chen","year":"2014","journal-title":"Hum Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2020.04.006","article-title":"[Effect and mechanism of low-dose chidamide on the treatment of primary immune thrombocytopenia]","volume":"41","author":"Zhao","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2003.11.001","article-title":"Mesenchymal stem cells: Clinical applications and biological characterization","volume":"36","author":"Barry","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2014.938320","article-title":"The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia","volume":"47","author":"Zhang","year":"2014","journal-title":"Autoimmunity"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.28405","article-title":"Mesenchymal stem cells improve platelet counts in mice with immune thrombocytopenia","volume":"120","author":"Zhang","year":"2019","journal-title":"J Cell Biochem"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03642.x","article-title":"Transplantation of adipose-derived mesenchymal stem cells into a murine model of passive chronic immune thrombocytopenia","volume":"52","author":"Xiao","year":"2012","journal-title":"Transfusion"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1160\/th11-08-0596","article-title":"Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients","volume":"107","author":"Ma","year":"2012","journal-title":"Thromb Haemost"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2017.4229","article-title":"Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: A two-year follow-up","volume":"13","author":"Wang","year":"2017","journal-title":"Exp Ther Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.15034","article-title":"Mesenchymal stem cell deficiency influences megakaryocytopoiesis through the Tnfaip3\/Nf-\u039ab\/Smad pathway in patients with immune thrombocytopenia","volume":"180","author":"He","year":"2018","journal-title":"Br J Haematol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-021-00547-7","article-title":"Bone marrow mesenchymal stem cell-derived exosomes induce the Th17\/Treg imbalance in immune thrombocytopenia through mir-146a-5p\/Irak1 axis","volume":"34","author":"He","year":"2021","journal-title":"Hum Cell"},{"key":"B101","doi-asserted-by":"crossref","DOI":"10.1038\/nri1886","article-title":"Competence and competition: The challenge of becoming a long-lived plasma cell","volume":"6","author":"Radbruch","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12696","article-title":"Bortezomib induces clinical remission and reduction of Adamts13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura","volume":"164","author":"Mazepa","year":"2014","journal-title":"Br J haematol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12614","article-title":"Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: A case report","volume":"54","author":"Yates","year":"2014","journal-title":"Transfusion"},{"key":"B105","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000000517","article-title":"Bortezomib for refractory immune-mediated thrombocytopenia purpura","volume":"25","author":"Beckman","year":"2018","journal-title":"Am J Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1186\/1752-1947-8-19","article-title":"A combination of bortezomib and rituximab yields a dramatic response in a woman with highly refractory immune thrombocytopenic purpura: A case report","volume":"8","author":"Vinayek","year":"2014","journal-title":"J Med Case Rep"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1172\/JCI65689","article-title":"B cell depletion in immune thrombocytopenia reveals splenic long-lived plasma cells","volume":"123","author":"Mah\u00e9vas","year":"2013","journal-title":"J Clin Invest"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-789578","article-title":"Baff and Cd4 T cells are major survival factors for long-lived splenic plasma cells in a b-Cell-Depletion context","volume":"131","author":"Thai","year":"2018","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.259481","article-title":"Efficacy, safety and immunological profile of combining rituximab with belimumab for adults with persistent or chronic immune thrombocytopenia: Results from a prospective phase 2b trial","volume":"106","author":"Mah\u00e9vas","year":"2021","journal-title":"Haematologica"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0800887","article-title":"Platelets, petechiae, and preservation of the vascular wall","volume":"359","author":"Nachman","year":"2008","journal-title":"New Engl J Med"},{"key":"B112","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/09537104.2017.1378807","article-title":"Endothelial alterations in a canine model of immune thrombocytopenia","volume":"30","author":"LeVine","year":"2019","journal-title":"Platelets"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-807248","article-title":"Atorvastatin enhances bone marrow endothelial cell function in corticosteroid-resistant immune thrombocytopenia patients","volume":"131","author":"Kong","year":"2018","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16426","article-title":"Combination of thrombopoietin receptor agonists, immunosuppressants and intravenous immunoglobulin as treatment of severe refractory immune thrombocytopenia in adults and children","volume":"189","author":"Gudbrandsdottir","year":"2020","journal-title":"Br J Haematol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-631937","article-title":"A novel triple therapy for itp using high-dose dexamethasone, low-dose rituximab, and cyclosporine (Tt4)","volume":"126","author":"Choi","year":"2015","journal-title":"Blood"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.7196","article-title":"Therapeutic effects of rituximab combined with cyclophosphamide on refractory idiopathic thrombocytopenic purpura","volume":"17","author":"Wang","year":"2019","journal-title":"Exp Ther Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-581868","article-title":"A multicenter randomized open-label study of rituximab plus rhtpo vs rituximab in corticosteroid-resistant or relapsed itp","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30170-9","article-title":"Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: A multicentre, randomised, open-label, phase 2 trial","volume":"4","author":"Feng","year":"2017","journal-title":"Lancet Haematol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1177\/20406207221097780","article-title":"Efficacy and safety of cyclosporine a treatment in autoimmune cytopenias: The experience of two Italian reference centers","volume":"13","author":"Fattizzo","year":"2022","journal-title":"Ther Adv In Hematol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.953716\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T17:45:52Z","timestamp":1676310352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.953716\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":119,"alternative-id":["10.3389\/fimmu.2022.953716"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.953716","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"article-number":"953716"}}